



Company name: Everads Therapy

Website: [www.everads-therapy.com](http://www.everads-therapy.com)

CEO name: Moshe Weinstein

Category: Biotech – Medical devices

Sessions: Illuminating the Path; Innovations and Challenges in Eye Care

- **Executive Summary / Investment Rationale**

Everads is focused on revolutionizing ocular drug delivery via the suprachoroidal space (SCS), an emerging administration route that allows safe and effective treatment of retinal and choroidal diseases. With few available technologies for accessing the SCS, our proprietary delivery system has successfully enabled easy and precise injections into this space. With a clinical proof of concept recently completed, which followed validation in in over 200 primate eyes, our results have driven several agreements with pharmaceutical and biotech companies, generating upfront fees and offering significant future royalty potential.

Our technology has been featured in multiple publications, presentations, and posters, reinforcing its value in ophthalmic treatment strategies.

- **Core Technology**

Our innovative delivery technology is designed to facilitate rapid and broad distribution within the SCS. This approach offers unique advantages:

Safe and effective administration targeting the outer retina and choroid, minimally invasive delivery without interference with the visual axis and potential extended durability for sustained therapeutic effect.

Unlike traditional microneedle-based techniques, our proprietary, geometrically optimized non-sharp tissue separator enables atraumatic access to the SCS, ensuring efficient and reliable drug delivery. Proven also in gene therapy applications, our delivery platform has demonstrated superior distribution capabilities, which have led to multiple pharmaceutical collaborations.



- **Product Profile / Pipeline**

Everads has recently completed recruitment in a first-in-human clinical trial that has demonstrated the tolerability and effectiveness of our technology as a safe and effective in-office injection (NCT06314217). Furthermore, our technology is currently being used to deliver a novel gene therapy developed by US-based Kriya Therapeutics for treating geographic atrophy (NCT06765980). Everads has also disclosed data from its co-development collaboration with VivaVision Biotech, developing a novel, potent, JAK inhibitor for treating posterior uveitis and other retinal diseases.

- **Business Strategy**

Our company is focused on driving revenue through strategic partnerships and licensing agreements with pharmaceutical and biotech companies. By fostering collaborations and validating our technology across various therapeutic applications, we are strengthening our market position.

In the short term, we are expanding preclinical investigational collaborations, while our long-term strategy includes developing an internal pipeline to commercialize proprietary treatments leveraging SCS delivery and remain committed to advancing our clinical collaboration programs

- **What's Next?**

We are progressing with new clinical programs, including a novel JAK inhibitor for retinal diseases, higher-volume SCS delivery, and cell therapy applications. Additionally, we are exploring the use of our technology for suprachoroidal bucking, broadening the scope of our technology applications.

Through ongoing research and expanding partnerships, we continue to shape the future of SCS technology, opening doors to new opportunities and market growth.

